EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hepatic arterial infusion chemotherapy plus camrelizumab and apatinib for advanced hepatocellular carcinoma

Mengxuan Zuo, Yuzhe Cao, Yi Yang, Guanglei Zheng, Da Li, Hongyan Shao, Qiaoyun Ma, Peng Song, Chao An, Wang Li

Hepatology International · 2024

DOI: 10.1007/s12072-024-10690-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology International, 2024. Verfasst von Mengxuan Zuo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People's Re…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Pyridines, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims There is limited information on combination of hepatic arterial infusion chemotherapy (HAIC) and systemic therapy for advanced hepatocellular carcinoma (Ad-HCC). We aim to compare the efficacy and safety of HAIC plus camrelizumab (a PD-1 inhibitor) and apatinib (an VEGFR-2 inhibitor) versus camrelizumab and apatinib for Ad-HCC.

Methods

From April 2019 to October 2022, 416 patients with Ad-HCC who received either HAIC plus camrelizumab and apatinib (TRIPLET protocol, n = 207) or camrelizumab and apatinib (C–A protocol, n = 209) were reviewed retrospectively. The propensity score matching (PSM) was used to reduce selective bias. Overall survival (OS) and progression-free survival (PFS) were compared using the Kaplan–Meier method with the log-rank test. Cox regression analyses of independent prognostic factors were evaluated.

Results

After PSM 1:1, 109 patients were assigned to two groups. The median OS of not reached in the TRIPLET group was significantly longer than that of 19.9 months in the C–A group ( p < 0.001), while in the TRIPLET group, the median PFS of 11.5 months was significantly longer than that of 9.6 months in the C–A group ( p < 0.001). Multivariate analyses showed that the factors significantly affected the OS were CTP grade, tumor number > 3, and TRIPLET treatment ( p < 0.001). Grade 3/4 adverse events occurred at a rate of 82.1% vs. 71.3% in TRIPLET and C–A groups, respectively.

Conclusion

The TRIPLET protocol has promising survival benefits in the management of patients with Ad-HCC, with acceptable safety. Trail registration : The study has been retrospectively registered at Chinese Clinical Trial Registry ( https://www.chictr.org.cn/ , ChiCTR2300075828).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPyridinesAntibodies, Monoclonal, HumanizedInfusions, Intra-ArterialAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedHepatic ArteryAdultAntineoplastic AgentsPropensity ScoreProgression-Free Survival

Stichwörter der Autor:innen

Combination therapyCox regression analysesInterventional treatmentKaplan–Meier methodOverall survivalPD-1 inhibitorProgression-free survivalPropensity score matchingSafetyVEGFR-2 inhibitor

Substanzen

apatinibcamrelizumabPyridinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
  • State Key Laboratory of Oncology in South China, Guangzhou, People's Republic of China.
  • Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, People's Republic of China.
  • Department of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
  • Department of Medical Oncology, Chinese PLA General Hospital, Beijing, People's Republic of China.
  • The Second Medical and National Clinical Research Center for Geriatric Disease, Beijing, People's Republic of China.

Zitieren

APA

Zuo, M., Cao, Y., Yang, Y., Zheng, G., Li, D., Shao, H., Ma, Q., Song, P., An, C., & Li, W. (2024). Hepatic arterial infusion chemotherapy plus camrelizumab and apatinib for advanced hepatocellular carcinoma. Hepatology International. https://doi.org/10.1007/s12072-024-10690-6

Vancouver

Zuo M, Cao Y, Yang Y, Zheng G, Li D, Shao H, et al. Hepatic arterial infusion chemotherapy plus camrelizumab and apatinib for advanced hepatocellular carcinoma. Hepatology International. 2024. doi:10.1007/s12072-024-10690-6

BibTeX
@article{Zuo2024,
  author = {Zuo, Mengxuan and Cao, Yuzhe and Yang, Yi and Zheng, Guanglei and Li, Da and Shao, Hongyan and Ma, Qiaoyun and Song, Peng and An, Chao and Li, Wang},
  title = {Hepatic arterial infusion chemotherapy plus camrelizumab and apatinib for advanced hepatocellular carcinoma},
  journal = {Hepatology International},
  year = {2024},
  doi = {10.1007/s12072-024-10690-6}
}
Kostenlos starten →